argenx SE American Depositary Shares (ARGX) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA...
argenx SE American Depositary Shares's revenue increased 88.6% year over year, from $2.25B to $4.25B.
Net income increased 55.1% over the same period, from $833.0M to $1.29B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 688% in total.
Total debt increased by 20.8% to $47.2M.
The debt-to-equity ratio stands at 0.01, indicating a conservative leverage profile.
argenx SE American Depositary Shares maintains a strong net profit margin of 30.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $539.4M | $-408.3M | $539.4M | $-348.7M | N/A | $2.85B | $11.5M | $2.53B |
| FY2022 | $445.3M-17.5% | $-709.6M | $415.8M | $-720.3M | N/A | $3.13B | $12.4M | $2.81B |
| FY2023 | $1.27B+184.9% | $-295.1M | $1.15B | $-425.0M | N/A | $4.54B | $20.0M | $4.10B |
| FY2024 | $2.25B+77.5% | $833.0M | $2.02B | $-21.7M | N/A | $6.20B | $39.1M | $5.50B |
| FY2025 | $4.25B+88.6% | $1.29B | $3.80B | $1.05B | N/A | $8.68B | $47.2M | $7.32B |
Balance Sheet Summary (Latest Period)
Total Assets
$8.68B
Total Liabilities
$1.36B
Total Equity
$7.32B
Cash & Equivalents
$4.44B
Total Debt
$47.2M
Current Assets
$6.90B
Current Liabilities
$1.32B
Retained Earnings
$-279.8M